SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lyka Labs Ltd (LYKALABS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500259 NSE: LYKALABS Pharmaceuticals & Drugs | Small Cap | Lyka Labs Share Price

₹60.27 2.87 (5.00%)

As on 04-Jun'26 16:59

Lyka Labs Ltd (LYKALABS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500259 NSE: LYKALABS Pharmaceuticals & Drugs | Small Cap | Lyka Labs Share Price

₹60.27 2.87 (5.00%)

As on 04-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹215 Cr.
Current Price
₹60.3
52-Week Low / High
₹44 / 125
TTM EPS
₹-9.1
TTM Sales
₹121 Cr.
Book Value per Share
₹24.4
P/E Ratio
0.00
Lower than its 5-year historical median
Industry PE
46.5
Price to Book (P/B)
2.47
Lower than its 5-year historical median
Price to Sales (P/S)
1.78
Lower than its 5-year historical median
EV/EBITDA
167.48
Higher than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
7.31%
Underperforms industry median
Return on Capital Employed (ROCE)
8.38%
Underperforms industry median
Return on Assets (ROA)
4.20%
Operating Profit Margin
13.3%
Net Profit Margin
6.11%
Gross Profit Margin
13.3%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
26.6%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
22.87%
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
58.16%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹51 Cr.
Equity
₹35.7 Cr.
Face Value
₹10
All Time Low / High
₹8.46 / 267.20

Lyka Labs stock performance

Key Ratios
mw4me loader

Check Before You Invest

Quality

Locked
Login to view analysis.

Valuation

Locked
Login to view analysis.

Price Trend

Locked
Login to view analysis.
Q.1 Is Lyka Labs Ltd a good quality company?
Lyka Labs Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Lyka Labs Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Lyka Labs Ltd vs industry peers?
Lyka Labs Ltd revenue CAGR is 27.02%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Lyka Labs Ltd?
Promoters hold 58.16% of the Lyka Labs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Lyka Labs Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -1.7% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Lyka Labs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 10.5%9%-1.8%-0.7%-20.9%4.5%47.3%-1%2.5%8.4%-
Value Creation
Index
-0.3-0.4-1.1-1.1-2.5-0.72.4-1.1-0.8-0.4-

Growth Parameters

Sales 76.47841.741.240.762.316480.6106135121
Sales YoY Gr.-2.2%-46.6%-1.2%-1.1%52.8%164%-51%32%26.6%-
Adj EPS 30.4-3.60.7-13.8-4.914-2.8-0.82.1-9.1
YoY Gr.--88.4%-1128.6%NA-2036.6%NANA-119.8%NANA-
BVPS (₹) 3833.434.134.86.61.515.519.227.337.824.4
Adj Net
Profit
6.70.8-10.12-39.4-13.940.2-8.5-2.57.6-32
Cash Flow from Ops. 10.320.26.818.3-11.55.876.56.93.13.3-
Debt/CF from Ops. 13.65.614.95-1228.11.710.418.411.6-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales 6.5%27%-6.4%26.6%
Adj EPS -3.9%NA-46.7%NA
BVPS-0.1%42%34.6%38.6%
Share Price -1.6% -2.5% -16.8% -48.6%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
7.81.1-11.92.1-67.2-120.2164.5-14.1-2.96.5-29.1
Op. Profit
Mgn %
13.327.9-1.22.2-7.923.259.319.413.713.3-1.9
Net Profit
Mgn %
8.71-24.34.9-96.8-22.424.5-10.6-2.45.6-26.7
Debt to
Equity
1.61.51.10.97.336.72.91.20.60.30.3
Working Cap
Days
46130160263349323010124721421088
Cash Conv.
Cycle
-54-509112962-25-670657917

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales57784241416216481106135
Operating Expenses + 505642404448676592117
Manufacturing Costs2333668989
Material Costs34362222202431294353
Employee Cost 7101110121316172634
Other Costs 77757512101420
Operating Profit 822-11-31497161518
Operating Profit Margin (%) 13.3%27.9%-1.2%2.2%-7.9%23.2%59.3%19.4%13.7%13.3%
Other Income + 12223323322
Exceptional Items 1-21-1-28-1-5-7-00
Interest 1317861926201252
Depreciation 3664881514126
Profit Before Tax 5-1-11-7-55-1860-13-111
Tax 0-0-0-90-420013
Profit After Tax 5-0-112-55-1440-13-28
PAT Margin (%) 8.4%-0.2%-26.0%4.2%-135.0%-23.2%24.3%-16.5%-2.1%6.1%
Adjusted EPS (₹)2.2-0.1-3.90.6-19.3-5.013.9-4.3-0.72.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Valuation of Lyka Labs - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 67749698194445990135
Share Capital 23222828292929313336
Reserves 43526870-10-2416285799
Debt +7273409113616182715534
Long Term Debt253557912615162634319
Short Term Debt4638361211102081215
Minority Interest0000000000
Trade Payables302821221712981114
Others Liabilities 60678627372074413023
Total Liabilities 228242243238209197209179186206

Fixed Assets

Net Fixed Assets +608681761029590665684
Gross Block100939493141163172154153189
Accumulated Depreciation40713173968828898104
CWIP 3024263026241816231
Investments 63626262323232323232
Inventories797664871012
Trade Receivables2624303071018172640
Cash Equivalents 21008715961
Others Assets 40343534282427323433
Total Assets 228242243238209197209179186206

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 820718-11677733
PBT 5-1-11-7-55-1860-13-111
Adjustment 322121055343831178
Changes in Working Capital -0-0715-12-9-21-11-11-14
Tax Paid -0-1-0-01-1-1-0-1-3
Cash Flow From Investing Activity + 5-5-3-300-47-9-13
Capex -5-5-3-3-1-1-66-9-13
Net Investments 00000000-0-0
Others 10000112110
Cash Flow From Financing Activity + -13-15-4-1620-8-63-2035
Net Proceeds from Shares 00340200452527
Net Proceeds from Borrowing 010-3174280-50-46-18-24
Interest Paid -11-16-6-6-6-6-22-10-7-2
Dividend Paid 0000000000
Others -2-8-1-84-4-19-1035
Net Cash Flow 0-0-1-08-29-7-3-5

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)8.07-0.27-12.781.79-94.98-124.71163.37-25.69-3.047.31
ROCE (%)10.479.01-1.8-0.7-20.894.4547.25-1.022.548.38
Asset Turnover Ratio0.260.360.180.170.180.310.810.420.580.69
PAT to CFO Conversion(x)1.6N/AN/A9N/AN/A1.93N/AN/A0.38
Working Capital Days
Receivable Days166.10108.50234265.60162.5048.4030.5078.7073.6089.70
Inventory Days58.6034.7071.1058.7052.2029.3013.9034.3028.3029.80
Payable Days371.50293.30419.10356.30358.60221.30122.40106.2081.3084.80

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Lyka Labs Ltd FAQs

The current trading price of Lyka Labs on 04-Jun-2026 16:59 is ₹60.27.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Lyka Labs stood at ₹215.1 Cr

The latest P/E ratio of Lyka Labs as of 03-Jun-2026 is 0.00.

The latest P/B ratio of Lyka Labs as of 03-Jun-2026 is 2.47.

The 52-week high of Lyka Labs is ₹125.0 and the 52-week low is ₹44.49.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Lyka Labs is ₹121 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Lyka Labs Ltd is a below average quality company.

The key valuation ratios of Lyka Labs Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Lyka Labs Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Lyka Labs Ltd

Lyka Labs Ltd was incorporated on December 29, 1976 as a private limited company and converted into a public limited company on  December 19, 1985.

The company is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.

Lyka Labs is committed to creating a better tomorrow for India. Maintaining a core competency in Lyophilization, allows Lyka Labs to supply Freeze Dried Drugs in sufficient quantities with the right quality. Lyka strives to manage this business in an ethical and transparent manner.

Lyka has 2 manufacturing facilities in Ankleshwar and Tarapur. There is also an R & D facility based in Chakala, Mumbai, and a corporate head office based in Andheri, Mumbai.

Plant located at Ankleshwar, Gujarat is one of the largest chemical Industrial estates in Asia. Located approx. 10 kms from the city of Bharuch, Gujarat. Ankleshwar is well connected and can be reached by road, rail or air from Mumbai, or by road and rail from Vadodara, or Ahmedabad.

Tarapur Plant is located in the MIDC Industrial Estate in Tarapur, District Thane, Maharashtra. Located approximately 80 kms from Mumbai City, and well connected by rail and road to Mumbai. 

Different business lines of the company:

  • Contract Manufacturing - Lyka undertakes manufacturing activities for a number of different companies on a Principal to Principal Basis. In most cases Lyka would undertake the entire manufacturing process, from sourcing of raw materials to manufacture to packaging, although Lyka also offers job work services where the raw materials are sourced by the client company. Their manufacturing processes are in line with world over best practices, as demonstrated by the ISO 9001:2002 Certification
  • Hospital Division - LYKA has forayed into marketing of products into hospitals/ institutions. To begin with, it has introduced a range of anti-infectives, which include systemic antimalarial, antifungal and antibacterials for serious infections. Apart from this, it has also introduced anesthetics, anti-ulcerants and steroid in parenteral dosage forms. On the anvil is the expansion of the range of the products in the above therapeutic segments as well as in the new therapeutic segments. The company also has plan to introduce products in solid dosage forms for hospitals / institutions.
  • Lyka Animal Health Care - Lyka Animal Healthcare Division within a short period has made strong presence in Indian Veterinary market with their quality innovative products. The animal healthcare division is managed and headed by veterinary professional with strong and dedicated team of field and in-house persons.
  • Generics - When generic products become available, the market competition often leads to substantially lower prices for both the original brand name product and the generic forms. Lyka markets branded generic products in the form of: -Tablets -Capsules -Ointments -Syrups Dry Powder and Liquids
  • Lyka BDR- Lyka manufactures and sells products to its Joint Venture company Lyka BDR. Lyka BDR is the largest seller of human and veterinary products in Sudan

Product range of the company includes:

  • Ampholyn Inj.  
  • Hydrolin Inj.   
  • Lyom Inj.   
  • Lypan Inj.   
  • Lypitaz Inj. 2.25g   
  • Lypitaz Inj. 4.5g   
  • Lyrab Inj.   
  • Lysunate Inj.  
  • Lysunate Tabs  
  • Lyvec Inj.   
  • Merojet Inj. 500mg   
  • Merojet Inj.1000mg   
  • Stropaz Inj.   
  • Thiolyn Inj. 500mg  
  • Thiolyn Inj.1000mg   
  • Vancolym Inj.   
  • Xolycef - SB Inj.   
  • Xolycef - TZ Inj.   
  • Xolycef Inj. 1000mg 
  • Zimtaz Inj. 

Achievements/ recognition:

  • ISO 9001:2000 certified
  • Recognized as in-house R&D Centre by Government of India, Ministry of Science & Technology, Department of Scientific and Industrial Research.
  • In 2011 the company has been conferred Certificate of Appreciation Patent Award by Pharmaceuticals Export Promotion Council.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×